“The decision to halt development of seladelpar was based on initial histological findings observed in the Phase 2b study of seladelpar in NASH,” says the company, noting histology characterized as an interface hepatitis presentation, with or without biliary injury.
A conference call is set for 4:30 PM ET.
CBAY -4% premarket
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.